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Abstract 
We adopted into RNA-sequencing technologies to construct the microRNA (miRNA) 
expression signature of head and neck squamous cell carcinoma (HNSCC). Our signature 
revealed that a total of 160 miRNAs (44 upregulated and 116 downregulated) were aberrantly 
expressed in cancer tissues. Expression of miR-150-5p (guide strand miRNA) and miR-150-3p 
(passenger strand miRNA) were significantly silenced in cancer tissues, suggesting both 
miRNAs act as antitumor miRNAs in HNSCC cells. Ectopic expression of mature miRNAs, 
miR-150-5p and miR-150-3p inhibited cancer cell aggressiveness. Low expression of miR-150-
5p and miR-150-3p predicted significantly shorter overall survival in patients with HNSCC (P = 
0.0091 and P = 0.0386) by Kaplan–Meier survival curves analyses. We identified that integrin 
α3 (ITGA3), integrin α6 (ITGA6), and tenascin C (TNC) were coordinately regulated by these 
miRNAs in HNSCC cells. Knockdown assays using siRNAs showed that ITGA3, ITGA6 and 
TNC acted as cancer promoting genes in HNSCC cells. Moreover, ITGA3, ITGA6, and TNC 
alterations were associated with significantly poorer overall survival (P = 0.0177, P = 0.0237, 
and P = 0.026, respectively). Dual strands of pre-150 (miR-150-5p and miR-150-3p) functioned 
as antitumor miRNAs based on the miRNA expression signature of HNSCC. Identification of 
antitumor miR-150-mediated RNA networks may provide novel insights into pathogenesis of 
HNSCC.  
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Introduction 
Despite advances in combination therapies involving surgery, radiotherapy, 
chemotherapy, and currently available molecular-targeted therapy for head and neck squamous 
cell carcinoma (HNSCC), the survival rate of patients with this disease has not improved [1-3]. 
HNSCC develops in the mucous membranes of the nasopharynx, oral cavity, oropharynx, 
larynx, and hypopharynx [4]. Among patients with HNSCC, hypopharyngeal squamous cell 
carcinoma is one of the most aggressive malignancies and has an extremely low survival rate 
due to the high rates of locoregional recurrence and distant metastasis [1, 5]. Control of cancer 
recurrence and metastasis may lead to improvement of HNSCC disease prognosis. Therefore, it 
is needed to improve our understanding of the molecular pathogenesis of HNSCC 
aggressiveness using current genomic-based strategies. 
MicroRNAs (miRNAs) act as fine-tuners that regulate the expression control of protein-
coding/protein-noncoding genes by sequence depending manner [6]. A vast extent of studies 
have reported that dysregulation of miRNA expression is involved in the pathogenesis of human 
cancers, including HNSCC [7, 8]. As a unique nature of miRNA biogenesis, a single miRNA 
can control thousands of target RNAs [9]. Thus, identification of novel cancer networks 
mediated by dysregulated miRNAs may provide insight into the pathogenesis and treatment of 
cancer. 
Current advanced genome-based technologies can identify abnormally expressed 
miRNAs in various types of cancer cells [10]. To identify differentially expressed miRNAs, we 
used clinical specimens to establish microarray-based, polymerase chain reaction (PCR)-based, 
and deep sequencing-based miRNA expression signatures [11-19]. From the HNSCC miRNA 
expression signature, we have identified the miR-29-family, miR-218, miR-451a, and the miR-
26-family acted as antitumor miRNAs and their miRNAs mediated metastasis-promoting 
pathways [13, 14, 20-22].  
In this study, we newly constructed the RNA sequencing-based miRNA expression 
signature of HNSCC using laryngeal and hypopharyngeal clinical specimens. Our present data 
showed that 160 miRNAs (44 upregulated and 116 downregulated) were aberrantly expressed in 
cancer tissues. Among the downregulated miRNAs, we focused on the dual strands of pre-miR-
150, i.e., miR-150-5p and miR-150-3p, in the HNSCC signature. Both of these miRNAs were 
markedly reduced in HNSCC tissues, indicating that these miRNAs may act as antitumor 
miRNAs in HNSCC cells. However, the roles of these miRNAs and their targets in HNSCC 
cells are still unclear.  
It is generally accepted in miRNA biogenesis that processing of the pre-miRNA through 
Dicer1 generates a miRNA duplex (a passenger strand and a guide strand). It is thought that 
guide strand of miRNA is incorporated into the RNA-induced silencing complex (RISC) to 
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target messenger RNAs, whereas the passenger strand of miRNA is degraded and has not 
functioned regulatory activity in cells [23-25]. The aim of this study was to investigate the 
antitumor functions of both strands of pre-miR-150 (miR-150-5p and miR-150-3p) and to 
identify their targeted oncogenic genes and pathways in HNSCC cells. Elucidation of antitumor 
miRNA-mediated cancer networks may provide novel insights into the molecular pathogenesis 
of HNSCC. 
 
 
Materials and Methods 
Clinical HNSCC specimens, cell lines, and RNA extraction 
A total of 22 clinical tissue specimens were collected from patients with HNSCC who 
underwent surgical resection at Chiba University Hospital between 2008 and 2014. 
Clinicopathological features of patients with HNSCC are summarised in Table 1. All patients in 
this study provided informed consent, and the study protocol was approved by the Institutional 
Review Board of Chiba University. 
Three human HNSCC cell lines, i.e., FaDu, SAS and HSC3, were investigated in this 
study. All cell lines were obtained from RIKEN Cell Bank (Tsukuba, Ibaraki, Japan). 
Total RNA, including miRNA, was isolated using TRIzol reagent (Invitrogen, Carlsbad, 
CA, USA). 
  
Small RNA deep sequencing and data mining 
To obtain the miRNA expression signature, we carried out high-throughput deep 
sequencing using Genome Analyzer IIx (Illumina, CA, USA) with 6 pairs of tumor and normal 
samples (Table 1). The procedures of small RNA sequencing and data mining were performed 
as described in our previous studies [16].  
 
Quantitative real-time reverse transcription PCR (qRT-PCR) 
PCR quantification was carried out essentially as previously described [14, 26-28]. To 
quantify the expression level of miRNAs, we utilised stem-loop qRT-PCR for miR-150-5p 
(assay ID: 000473; Applied Biosystems, Foster City, CA, USA) and miR-150-3p (assay ID: 
002637; Applied Biosystems) following the manufacturer's protocol. TaqMan probes and 
primers for ITGA3 (Hs01076873_m1; Applied Biosystems), ITGA6 (Hs01041011_m1), TNC 
(assay ID: Hs01115665_m1), CAV2 (Hs00184597_m1), and XIAP (Hs00745222_s1) were 
assay-on-demand gene expression products. mRNA and miRNA data were normalised to human 
GUSB (assay ID: Hs99999908_m1; Applied Biosystems) and RNU48 (assay ID: 001006; 
Applied Biosystems), respectively. 
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Transfection of miRNA mimic and small interfering RNA (siRNA) into HNSCC cells  
HNSCC cells were transfected with miRNA mimics for gain-of-function experiments and 
siRNAs for loss-of-function experiments. Pre-miR miRNA precursors (miR-150-5p, P/N: 
PM10070; miR-150-3p, P/N: PM12324; and negative control miR, P/N: AM17111; Applied 
Biosystems) were used in these assays. The following siRNAs were used in this study: stealth 
select RNAi siRNA, siITGA3 (P/N: HSS105531 and HSS179967; Invitrogen), siITGA6 (P/N: 
HSS179958 and HSS179959), and siTNC (P/N: HSS105145 and HSS105147). For transfection, 
RNAs were incubated with OPTI-MEM (Invitrogen) and Lipofectamine RNAiMax reagent 
(Invitrogen), as previously described [14, 26-28]. 
 
Cell proliferation, migration, and invasion assays 
Cell proliferation, migration and invasion assays were described previously [14, 26-28]. 
 
Incorporation of miR-150-5p or miR-150-3p into RISC by Ago2 immunoprecipitation 
SAS cells were transfected with 10nM miRNA by  
Reverse transfection. After 48h, immunoprecipitation was performed using a microRNA 
isolation kit, Human Ago2 (Wako, Osaka, Japan) according to the manufacturer’s protocol. 
Expression levels of miR-150-5p or miR-150-3p were measured by RT-qPCR methods. 
Detection of miRNA data were normalized to the expression of miR-26a (assay ID: 000404; 
Applied Biosystems), which was not affected by miR-150-5p and miR-150-3p. 
 
Identification of putative genes regulated by miR-150-5p and miR-150-3p in HNSCC cells 
Specific genes regulated by miR-150-5p and miR-150-3p were identified by a 
combination of in silico and genome-wide gene expression analyses. Genes regulated by miR-
150-5p and miR-150-3p were listed using the TargetScan database. Oligo microarray (Agilent 
Technologies; Human GE 60K) was used for gene expression analysis. The microarray data 
were deposited into GEO (http://www.ncbi.nlm.nih.gov/geo/), with accession number 
GSE82108. Upregulated genes in HNSCC were obtained from publicly available data sets in 
GEO (accession number: GSE9638). To identify signalling pathways regulated in silico, gene 
expression data were analysed using the KEGG pathway categories with the GeneCodis 
program. 
 
Immunohistochemistry 
The formalin-fixed paraffin-embedded (FFPE) tissues were used. The patients’ 
backgrounds and clinicopathological characteristics are summarized in Table 1. Tissue sections 
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were incubated overnight at 4˚C with anti-ITGA3 antibodies diluted 1:100 (HPA008572; 
Sigma-Aldrich), anti-ITGA6 antibodies diluted 1:100 (HPA012696; Sigma-Aldrich) and anti-
ITGA3 antibodies diluted 1:50 (#SC-20932; Santa Cruz Biotechnology). The procedure for 
immunohistochemistry was described previously [27, 29]. 
 
Western blotting 
Immunoblotting was performed with rabbit anti-ITGA3 antibodies (1:250 dilution, 
HPA008572; Sigma-Aldrich, St. Louis, MO, USA), anti-ITGA6 antibodies (1:500 dilution, 
HPA012696; Sigma-Aldrich), and anti-TNC antibodies (1:400 dilution, #sc-20932; Santa Cruz 
Biotechnology, Dallas, TX, USA); anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
antibodies (1:1000 dilution, ab8245; Abcam, Cambridge, UK) were used as an internal control. 
The procedures were described in our previous studies [14, 26-28]. 
 
The Cancer Genome Atlas (TCGA) database analysis of HNSCC specimens 
The clinical significance of ITGA3, ITGA6, and TNC in HNSCC was assessed by RNA 
sequencing and by using a putative copy number variation (CNV) database (predicted by the 
GISTIC algorithm) in HNSCC-TCGA (https://tcga-data.nci.nih.gov/tcga/). The genomic and 
clinical data were retrieved from cBioportal (http://www.cbioportal.org/) [30] or UCSC Cancer 
Browser (https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/) [31], which were downloaded 
on June 17, 2016. Specimens with alterations in ITGA3, ITGA6, and TNC and specimens 
without alterations were analysed by Kaplan–Meier survival curves and log-rank statistics. 
Heatmap of gene expression was generated by cBioportal. The P-values and log odds ratio of 
co-occurrence are determined by Fisher's exact test. Detail information on the method is 
described in previous paper [30]. 
 
Statistical analysis 
Relationships between expression values in 2 conditions or variables were analysed using 
the Mann-Whitney U test or Bonferroni-adjusted Mann-Whitney U test. Spearman’s rank test 
was used to evaluate the correlations between the expression of miR-150-5p or miR-150-3p and 
target genes. We used Expert StatView software (version 5.0 SAS Institute Inc., Cary, NC, 
USA) for these analyses. 
 
 
Results 
Sequencing of small RNAs and construction of the miRNA expression signature of HNSCC 
To prepare the miRNA expression signature of HNSCC, we performed small RNA 
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sequencing of 6 HNSCC samples (Table 1). Initially, 12,180,452 to 24,845,427 raw sequence 
reads were analysed for the small RNA libraries (Supplementary Table 1). After filing and 
trimming of the sequenced reads, from 5,690,747 to 15,951,587 locations aligned uniquely and 
multiply matched reads were obtained (Supplementary Table 2). All of the sequenced reads 
(larger than 19 nucleotides) were assigned on the human genome, and these human genome-
matched sequenced reads were divided into small RNAs according to their biological features 
(Supplementary Table 3). 
In this study, a total of 116 downregulated miRNAs and 44 upregulated miRNAs were 
detected from aligned reads using R program (Tables 2a and 2b).  
 
Expression levels of miR-150-5p and miR-150-3p in HNSCC clinical specimens and cell 
lines 
The stem-loop sequence of miR-150 and the mature sequences of miR-150-5p and miR-
150-3p are shown in Supplementary Figure 1A. Database (http://www.mirbase.org/) indicates 
that miR-150-5p is recognized as a guide strand and miR-150-3p as a passenger strand.  
Expression levels of miR-150-5p and miR-150-3p in HNSCC tissues (n = 22), normal 
epithelial tissues (n = 22), and three HNSCC cell lines (including FaDu, SAS and HSC3 cells) 
were evaluated. Clinical features of patients with HNSCC are summarised in Table 1. The 
expression levels of miR-150-5p and miR-150-3p were markedly lower in tumor tissues and 
HNSCC cell lines than in normal epithelial tissues (P = 0.0048 and P = 0.0027, respectively, 
Figure 1A). Spearman’s rank tests showed positive correlations between the expression of miR-
150-5p and miR-150-3p (R = 0.626 and P < 0.0001; Figure 1A).  
A large cohort analysis (n = 330) using data from the TCGA database revealed that low 
expression of miR-150-5p and miR-150-3p predicted the overall survival of HNSCC patients (P 
= 0.0091 and p = 0.0386, respectively; Figure 1B). 
  
Both strands of miRNAs (miR-150-5p and miR-150-3p) incorporated into RISC in SAS 
cells. 
We hypothesized that passenger strand of miR-150-3p might be incorporated into the 
RISC and functioned in cancer cells. We performed immunoprecipitation with antibodies 
targeting Ago2, which plays a central role in the RISC. After transfection with miR-150-5p or 
miR-150-3p, Ago2-bound miRNAs were isolated, and RT-qPCR was carried out to determine 
whether miR-150-5p and miR-150-3p bound to Ago2 (Supplementary Figure 1B). 
After transfection with miR-150-5p and immunoprecipitation by anti-Ago2 antibodies, 
detection level of miR-150-5p was significantly higher than those of mock- or miR-control-
transfected cells and those of miR-150-3p-transefected SAS cells (P < 0.0001; Supplementary 
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Figure 1C). Likewise miR-150-5p transfection, miR-150-3p was detected by Ago2 
immunoprecipitation (P < 0.0001; Supplementary Figure 1C). 
 
Ectopic expression effects of miR-150-5p and miR-150-3p in HNSCC cell lines  
The anti-tumor roles of miR-150-5p and miR-150-3p were in investigated by using mature 
miRNA transfection into cancer cell lines, FaDu, SAS and HSC3.  
Cancer cell proliferations were inhibited by transfected with miR-150-5p or miR-150-3p 
in comparison with mock or control transfectants (*P < 0.0001, **P < 0.0005, respectively; 
Figure 1C). Migration activities were significantly suppressed after transfection with miR-150-
5p or miR-150-3p (P < 0.0001, Figure 1D). Similarly, invasion assays showed that transfection 
with miR-150-5p or miR-150-3p significantly suppressed cell invasion activity (P < 0.0001; 
Figure 1E). 
Synergistic effects of miR-150-5p and miR-150-3p were investigated by proliferation and 
migration assays with co-transfection of miR-150-5p and miR-150-3p in FaDu cells. There were 
no apparent synergistic effects following co-transfection with these miRNAs (Supplementary 
Figures 2A and 2B). 
 
Identification of putative target genes regulated by both miR-150-5p and miR-150-3p in 
HNSCC cells 
To identify putative target genes coordinately regulated by miR-150-5p and miR-150-3p, 
we performed applied to combination of in silico analyses, oligomicroarray expression analyses, 
and Gene Omnibus database (GEO) analyses. Our strategy for selection of putative target genes 
that were coordinately regulated by miR-150-5p and miR-150-3p is shown in Figure 2A.  
The TargetScan database (release 7.0) showed that 6,410 and 2,558 genes had putative 
target sites for miR-150-5p and miR-150-3p, respectively. First, we analysed genome-wide gene 
expression assays using FaDu cells (GEO accession number: GSE82108). A total of 1,987 and 
849 genes were downregulated in miR-150-5p and miR-150-3p transfectants, respectively, and 
had putative binding sites in their 3’-UTRs. Next step, to evaluate upregulated genes in clinical 
HNSCC samples (GEO accession number: GSE9638). We identified 1,257 and 525 genes as 
putative target genes for miR-150-5p and miR-150-3p, respectively, in HNSCC cells.  
Finally, we categorised these putative target genes into Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways using the GeneCodis database, and 52 and 5 pathways were listed 
as putative miR-150-5 and miR-150-3p regulated pathways (Tables 3 and 4). Among these 
pathways, we focused on the focal adhesion pathway because both miR-150-5p and miR-150-3p 
markedly inhibited cancer cell migration and invasion (Figures 1D and 1E). Five genes (TNC, 
ITGA3, ITGA6, CAV2, and XIAP) were found to be regulated by both miR-150-5p and miR-150-
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3p in this pathway (Tables 5 and 6).  
We next performed qRT-PCR analyses of 3 HNSCC cell lines to investigate whether 
restoration of miR-150-5p or miR-150-3p expression altered the mRNA expression of these 5 
genes. The mRNA expression levels of these 5 candidate genes are shown in Figure 3A and 
Supplementary Figure 3A. Among 5 genes, we focused on ITGA3, ITGA6, and TNC genes 
because aberrant integrin-mediated signalling promoted cancer cell aggressiveness according to 
our previous studies [21, 22, 29]. Moreover, two genes CAV and XIAP have been involved in 
cancer pathogenesis including HNSCC by past studies [32-35]. The analysis of the expression 
control of these two genes by miRNAs is important theme. 
 
Regulation of ITGA3, ITGA6, and TNC expression by miR-150-5p and miR-150-3p in 
HNSCC clinical specimens and HNSCC cells 
Next, we investigated the mRNA expression levels of ITGA3, ITGA6, and TNC in 22 
HNSCC clinical specimens by qRT-PCR. ITGA3, ITGA6, and TNC were significantly 
upregulated in HNSCC tissues (P = 0.0004, P = 0.0023, and P = 0.0063, respectively; Figure 
2B). Spearman’s rank tests showed a negative correlation between the expression levels of these 
3 genes and miR-150-5p (P = 0.001, P = 0.0029, and P = 0.0004, respectively; R = -0.503, R = -
0.455, and R = -0.542, respectively; Figure 2C) and between the expression of these 3 genes and 
miR-150-3p (P = 0.0081, P = 0.0185, and P = 0.0068, respectively; R = -0.404, R = -0.359, and 
R = -0.413, respectively; Figure 2D).  
Next, we investigated whether ITGA3, ITGA6, and TNC expression was reduced by 
restoration of miR-150-5p and miR-150-3p in HNSCC cells. Expression levels of these 3 genes 
were markedly repressed in miR-150-5p and miR-150-3p transfectant cells compared with that 
in mock-transfected cells (Figures 3A and 3B).  
The synergistic effects of miR-150-5p and miR-150-3p were evaluated the mRNA 
expression levels of ITGA3, ITGA6, and TNC with co-transfection of miR-150-5p and miR-150-
3p in FaDu cells. However, no synergistic effects were observed (Supplementary Figure 3B). 
 
Immunohistochemical detection of ITGA3, ITGA6 and TNC in HNSCC clinical specimens 
We also examined the expression levels of ITGA3, ITGA6 and TNC in HNSCC clinical 
specimens by immunohistochemical staining. ITGA3 and ITGA6 were strongly expressed in 
several cancer tissues (Figure 4). TNC was moderately expressed in cancer lesions (Figure 4). 
While low expression was observed in noncancerous regions (Figure 4). 
 
Effects of ITGA3, ITGA6, and TNC knockdown on cell proliferation, migration, and 
invasion in FaDu cells 
9 
 
To investigate the oncogenic functional of ITGA3, ITGA6, and TNC in FaDu cells, we 
applied to loss-of-function assays using siRNAs. First, we evaluated the knockdown efficiency 
of si-ITGA3, si-ITGA6, and si-TNC transfection in FaDu cells. Knockdown efficiencies of 
siRNAs, si-ITGA3, si-ITGA6, and si-TNC were shown in Figures 5A and 5B. 
Cancer cells proliferations were significantly reduced in si-ITGA3-1 and si-TNC 
transfectants in comparison with that in mock-transfected FaDu cells (Figure 5C). In contrast, 
proliferation was not inhibited in FaDu cells transfected with si-ITGA3-2 and si-ITGA6. 
Migration activities were significantly suppressed in si-ITGA3, si-ITGA6, and si-TNC 
transfectants in comparison with that in mock-transfected FaDu cells (Figure 5D). As like as 
migration assays, invasion activity was significantly inhibited in si-ITGA3, si-ITGA6, and si-
TNC transfectants in comparison with that in mock-transfected FaDu cells (Figure 5E). 
 
Clinical significance of ITGA3, ITGA6, and TNC expression in HNSCC 
To investigate the clinical significance of ITGA3, ITGA6, and TNC in HNSCC, we 
analysed their associations with tumor stage and lymph node stage using the TCGA-PRAD 
database. The mRNA expression levels of ITGA3, ITGA6, and TNC were significantly 
upregulated in HNSCC clinical samples (Figure 6A). 
Heatmap visualization of gene expression showed all gene pairs among three genes 
expression pattern (mRNA Z-score > 0) show significant co-occurrence (Figure 6B). 
Next, to examine whether the expression levels of these genes predicted overall survival, 
patients were divided into two groups: Z-score > 0 and Z-score ≤ 0. Higher ITGA3, ITGA6, and 
TNC expression levels were associated with shorter overall survival (P = 0.0177, P = 0.0237, P 
= 0.026, respectively; Figure 6C). Details of mRNA expression z-scores are described in Figure 
7A. The distributions of ITGA3, ITGA6, and TNC genomic copy number variations are shown in 
Figure 7B and 7C. 
Multivariate Cox proportional hazards models were used to assess independent predictors 
of progression-free survival, including expression level of the gene (Z score > 0 versus Z score 
≤ 0), tumor stage (T3 and T4 versus T1 and T2), lymph node stage (N+ versus N-), age at 
diagnosis (> 60 years versus ≤ 60 years), histologic grade (G3 and G4 versus G1 and G2), and 
sex (male versus female). High ITGA3 expression was a significant prognostic factor in patients 
with HNSCC (hazard ratio [HR] = 1.485, 95% confidence interval [CI] = 1.082–2.035, P = 
0.0146; Figure 6D). Likewise, high ITGA6 expression (HR = 1.437, 95% CI = 1.043–1.975, P = 
0.0268) was a significant prognostic factor (Figure 6D). Furthermore, the expression of ITGA3, 
ITGA6 and TNC genes were significantly higher in the T3 and T4 group than in the T1 and T2 
group (HR = 2.063, HR = 2.133, HR = 2.083, respectively; P < 0.0001; Figure 6D). 
From the data of the TCGA database, the expression level of miR-150-5p and miR-150-3p 
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were extracted for each TNM stage and T stage. The expression level of miR-150-5p and miR-
150-3p was significantly decreased in advanced cases. The expression level of miR-150-5p and 
miR-150-3p were significantly decreased in advanced T stage cases (Figure 8). 
 
 
Discussion 
The control of intercellular protein-coding/noncoding RNA expression is tightly regulated 
by miRNA [6]. Therefore, dysregulation of miRNAs can profoundly impact normal cell 
physiology and enhance oncogenesis. Identification of oncogenic and antitumor miRNAs has 
led us to elucidate novel miRNA-mediated cancer networks. We have sequentially obtained the 
miRNA expression signatures of several types of cancers and used these signatures to 
identify antitumor miRNA-mediated cancer pathways [11-19, 36]. Deep sequencing technology 
can be used to illuminate the miRNA expression signatures of cancer cells. In this study, we 
created deep sequencing-based miRNA expression signatures using laryngeal and 
hypopharyngeal squamous cell carcinoma clinical specimens. 
Our signature included several antitumor miRNAs (miR-375, miR-133a, and miR-1 etc.) 
that had been identified in human cancers in previous studies [26, 27, 37-43], suggesting that 
our present signature was effective for identification of novel oncogenic and antitumor miRNAs 
in HNSCC cells and may provide a benchmark for future studies of HNSCC. Interestingly, our 
present signature revealed that both strands of pre-miR-150, i.e., miR-150-5p and miR-150-3p 
were significantly downregulated in this signature. Our recent studies demonstrated that both 
strands of pre-miR-144 (miR-144-5p: guide strand and miR-144-3p: passenger strand) and pre-
miR-145 (miR-145-5p: guide strand and miR-145-3p: passenger strand) inhibited cancer cell 
aggressiveness [44-46]. These findings suggested that passenger strand of miRNAs had 
antitumor function in several cancer cells. Therefore, we focused on miR-150-5p and miR-150-
3p and investigated the antitumor functional of these miRNAs in HNSCC cells. 
Our present data demonstrated that both miR-150-5p and miR-150-3p were significantly 
reduced in cancer tissues, and ectopic expression of each miRNA markedly inhibited cancer cell 
aggressiveness. These data indicated that both strands of miR-150-5p and miR-150-3p 
functioned as antitumor miRNAs in HNSCC cells. Past studies have reported the aberrant 
expression of miR-150-5p in various cancers, suggesting that this miRNA contributes 
significantly to cancer pathogenesis [47]. However, the expression status of miR-150-5p was 
varied according to cancer type, indicating that miR-150-5p was a multifunction molecule with 
both oncogenic and antitumor functions depending on the cancer type [47]. In contrast, the 
functional significance of miR-150-3p in human cancer is still unclear. Our present study is the 
first report demonstrating that miR-150-3p acts as an antitumor miRNA, similar to miR-150-5p, 
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in HNSCC cells. 
Molecular mechanism of silencing of miR-150-5p and miR-150-3p in HNSCC cells is still 
obscure. To investigate these miRNAs expression and DNA methylation, SAS cells were 
treated with the demethylating agent (5-aza-dC). Expression of miR-150-5p was significantly 
elevated after 5-aza-dC treatment (Supplementary Figure 4). On the other hand, expression of 
miR-150-3p was slightly upregulated by 5-aza-dC treatment (Supplementary Figure 4). These 
data suggested that DNA methylation might be contributed to silencing of miR-150-5p and miR-
150-3p in HNSCC cells. 
We also evaluated the roles of miR-150-5p and miR-150-3p in regulating genes and 
pathways in HNSCC cells. We hypothesised that miR-150-5p and miR-150-3p may coordinately 
regulate target genes associated with HNSCC pathogenesis. To identify miRNA-regulated 
targets and pathways, we applied in silico and gene expression analyses, as described in our 
previous studies [13-17, 44]. Here, we identified 5 putative candidate genes involved in the 
focal adhesion pathway (TNC, ITGA3, ITGA6, CAV2, and XIAP) that were regulated by both 
miR-150-5p and miR-150-3p in HNSCC cells. Among these genes, our previous studies 
demonstrated that ITGA3, ITGA6, and CAV2 were overexpressed in cancer tissues and 
associated with cancer cell migration and invasion [22, 29, 33]. Moreover, ITGA3, ITGA6, and 
CAV2 have been shown to be directly regulated by antitumor miRNAs, i.e., miR-223, miR-29s, 
and miR-218, respectively [22, 29, 33]. In this study, we focused on TNC and investigated its 
functional roles in HNSCC. 
TNC is a multifunctional extracellular matrix (ECM) glycoprotein composed of several 
distinct domains [48]. Expression of TNC in adult tissue is restricted, except in the context of 
inflammation and tissue injury [48]. Cancer cells and corresponding stromal cells also 
exhibit TNC expression, and high expression of TNC has been reported in several cancers [48-
50]. Overexpression of TNC induces ECM deposition, and aberrant activation of ECM-mediated 
signalling promotes cancer cell aggressiveness, and the epithelial-mesenchymal transition 
(EMT) [48-50]. Several studies have demonstrated that TNC binds directly to integrins, and 
TNC/integrin-mediated signalling contributes to embryonic development, tissue repair, and 
cancer pathogenesis [49, 51]. Our previous studies showed that overexpression of ITGA6/B4 
and ITGA3/B1 was involved in cancer cell migration and invasion in HNSCC and prostate 
cancer [22, 29]. Moreover, a recent study showed that ITGA6 is a hypoxia-inducible factor 
(HIF)-dependent transcriptional target gene and that ITGA6 expression is an independent 
prognostic factor in patients with breast cancer [52]. 
Our large cohort study using TCGA datasets indicated that the expression levels of 
ITGA3, ITGA6, and TNC were upregulated in cancer tissues. Furthermore, Kaplan–Meier 
survival curves revealed that high expression of these genes predicted poorer survival in patients 
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with HNSCC. Our functional study showed that silencing of ITGA3, ITGA6, and TNC inhibited 
HNSCC cell migration and invasion. Metastasis is responsible for most of the mortality in 
patients with HNSCC. Therefore, activation of TNC/integrin receptor-mediated signalling may 
be a putative target in cancer treatment. 
In conclusion, downregulation of dual strands of pre-miR-150 (miR-150-5p and miR-150-
3p) was detected by deep sequencing-based miRNA signature analysis. The antitumor functions 
of these miRNAs coordinately regulate focal adhesion pathway-related genes in HNSCC cells. 
The expression of ITGA3, ITGA6, and TNC is involved in HNSCC pathogenesis. Identification 
of novel cancer networks mediated by aberrantly expressed miRNAs and antitumor miRNAs 
may improve our understanding of HNSCC molecular pathogenesis. Our newly created deep 
sequencing-based miRNA signature provides a basis for further HNSCC research. 
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Figure Legends 
Figure 1: Expression levels of miR-150-5p and miR-150-3p in HNSCC clinical specimens and 
functional significance of miR-150-5p and miR-150-3p in HNSCC cells. 
(A) Expression levels of miR-150-5p and miR-150-3p in HNSCC clinical specimens and cell 
lines. RNU48 was used as an internal control. Spearman's rank test showed a positive 
correlation between the expressions of miR-150-5p and miR-150-3p. (B) Kaplan–Meier survival 
curves, as determined using data from the TCGA database. (C) Cell proliferation was 
determined by XTT assay 72 h after transfection with miR-150-5p and miR-150-3p. *P < 
0.0001, **P < 0.0005. (D) Cell movement was assessed by migration assays 48 h after 
transfection with miR-150-5p and miR-150-3p. *P < 0.0001. (E) Cell invasion was characterised 
by invasion assays 48 h after transfection with miR-150-5p and miR-150-3p. *P < 0.0001. 
 
Figure 2: Identification of miR-150-5p and miR-150-3p target genes and expression levels of 
three genes in HNSCC clinical specimens. 
(A) Flow chart depicting the strategy for identification of miR-150-5p and miR-150-3p target 
genes. (B) Expression levels of ITGA3, ITGA6, and TNC in HNSCC clinical specimens and cell 
lines. GUSB was used as an internal control. (C) The negative correlation between gene 
expression and miR-150-5p. Spearman’s rank test was used to evaluate the correlation. (D) The 
negative correlation between gene expression and miR-150-3p. Spearman’s rank test was used 
to evaluate the correlation. 
 
 
Figure 3: Regulation of target gene expression by miR-150-5p and miR-150-3p in HNSCC cell 
lines. 
(A) Expression levels of ITGA3, ITGA6, and TNC mRNAs 72 h after transfection with 10 nM 
miR-150-5p or miR-150-3p into cell lines. GUSB was used as an internal control. *P < 0.0001, 
**P < 0.008. (B) Protein expression of ITGA3, ITGA6, and TNC 72 h after transfection with 
miR-150-5p or miR-150-3p. GAPDH was used as a loading control. 
 
Figure 4: Immunohistochemical staining of ITGA3, ITGA6 and TNC in clinical specimens of 
HNSCC. 
ITGA3 and ITGA6 were strongly expressed in cancer lesions, while TNC was moderately 
expressed in cancer lesions. (100X and 400X magnification field). 
 
Figure 5: Effects of ITGA3, ITGA6, and TNC silencing by siRNA transfection in FaDu cells. 
(A) ITGA3, ITGA6, and TNC mRNA expression 72 h after transfection with 10 nM siRNA into 
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FaDu cells. GUSB was used as an internal control.*P < 0.0001. (B) ITGA3, ITGA6, and TNC 
protein expression 72 h after transfection with siRNA. GAPDH was used as a loading control. 
(C) Cell proliferation was determined by XTT assay 72 h after transfection with siRNA. *P < 
0.001. (D) Cell movement was assessed by migration assay 48 h after transfection with siRNA. 
*P < 0.0001. (E) Cell invasion was characterised by invasion assay 48 h after transfection with 
siRNA. *P < 0.0001. 
 
Figure 6: Clinical significance of three genes and miR-150-5p and miR-150-3p expression in 
HNSCC based on data from the TCGA database. 
(A) Comparison of ITGA3, ITGA6, and TNC mRNA expression levels between normal and 
tumor samples in TCGA database. (B) Heatmap visualization of gene expression based on 
TCGA-HNSCC RNA Seq data (Upper). All gene pairs among three genes expression pattern 
(mRNA Z-score > 0) showed significant co-occurrence by Fisher's exact test (Lower). (C) 
Clinical outcomes in patients with altered miR-150-5p and miR-150-3p expression (CNV: 
amplification or gain, or mRNA: Z-score > 0) or without altered miRNA expression (CNV: 
diploid or het loss, and mRNA: Z-score ≤ 0), as displayed using Kaplan–Meier plots with log-
rank tests. (D) Forest plot summarising hazard ratios. The X-axis displays the hazard ratio and 
95% CI of each subgroup.  
 
Figure 7: 
(A, B) Distributions of ITGA3, ITGA6, and TNC mRNA Z-scores (n = 522) and genomic copy 
number variations (n = 522) in HNSCC, as determined using data from TCGA. (C) Box-and-
whisker plots of ITGA3, ITGA6, and TNC mRNA expression with respect to genomic copy 
number. 
 
Figure 8: 
Expression of miR-150-5p and miR-150-3p according to TNM stage and T stage (compared with 
T1 or stage I). From the data of the TCGA database, the expression level of miR-150-5p and 
miR-150-3p was significantly decreased in advanced cases and advanced T stage cases. *P < 
0.05, **P < 0.01. 
 
Supplementary Figure 1: Both strands of miR-150-5p and miR-150-3p incorporated into RISC. 
(A) Stem-loop sequence of miR-150 with red characters indicating mature miRNAs was shown. 
Mature miRNA sequences of miR-150-5p and miR-150-3p were shown, miR-150-5p was 
recognized as guide strand, whether miR-150-3p as passenger strand by miRBase 
(http://www.mirbase.org/). (B) Schematic illustration of miRNA detection method. Isolation of 
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RISC incorporated miRNAs by Ago2 immunoprecipitation. (C) Expression levels of miR-150-
5p and miR-150-3p after transfection with miR-150-5p or miR-150-3p following 
immunoprecipitation by Ago2 (P < 0.0001). 
 
Supplementary Figure 2: The synergistic effects of miR-150-5p and miR-150-3p on HNSCC 
cells. 
(A) Cell proliferation was determined by XTT assay 72 h after transfection with 10 nM miR-
150-5p and miR-150-3p. *P < 0.0001. (B) Cell movement was assessed by migration assay 48 h 
after transfection with 10 nM miR-150-5p and miR-150-3p. *P < 0.0001.  
 
 
Supplementary Figure 3: Regulation of target gene expression by miR-150-5p and miR-150-3p 
and the synergistic effects of miR-150-5p and miR-150-3p on the genes. 
(A) Expression of CAV2 and XIAP mRNAs 72 h after transfection with 10 nM miR-150-5p or 
miR-150-3p into cells. GUSB was used as an internal control. *P ≤ 0.0001, **P < 0.001. (B) 
Expression levels of ITGA3, ITGA6, and TNC 72 h after transfection with 10 nM miR-150-5p 
and/or miR-150-3p in HNSCC cells. GUSB was used as an internal control. *P < 0.0001, **P < 
0.005. 
 
Supplementary Figure 4: Effects of demethylating agent (5-aza-dC) treatment on HNSCC 
cells.  
Cell were exposure to 5-aza-dC (1 μM). After 72 hours, expression levels of miR-150-5p and 
miR-150-3p were measured by PCR methods. RNU48 was used as normalization. 
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Table 1. Clinical features of 22 HNSCC patients     
No. Age Sex Location T N M Stage Differentiaion Remarks 
1 66 M hypopharynx 2 2c 0 IVa moderate deep sequencing 
2 66 M hypopharynx 4b 2c 0 IVb moderate deep sequencing 
3 45 M hypopharynx 4a 2c 0 IVa moderate deep sequencing 
4 75 M hypopharynx 4a 2c 0 IVa well deep sequencing 
5 82 M larynx 4a 0 0 IVa moderate deep sequencing 
6 50 M larynx 4a 2b 0 IVa moderate deep sequencing 
7 58 M hypopharynx 4a 0 0 IVa well IHC staining 
8 76 M hypopharynx 4a 1 0 IVa well  
9 66 M hypopharynx 4a 2c 0 IVa well  
10 74 M hypopharynx 4a 2c 0 IVa poor  
11 69 M larynx 3 0 0 III well  
12 85 M larynx 3 2b 0 IVa moderate  
13 70 M larynx 4a 1 0 IVa well-moderate  
14 84 M larynx 4a 0 0 IVa moderate  
15 74 M tongue 1 0 0 I well  
16 66 M tongue 2 0 0 II moderate IHC staining 
17 73 M tongue 3 1 0 III poor  
18 72 M tongue 4a 2b 0 IVa moderate  
19 83 M oral floor 2 1 0 III well  
20 77 M oral floor 2 2b 0 IVa moderate  
21 68 F oral floor 4a 1 0 IVa well  
22 69 M orophalynx 1 0 0 I well   
 
Table 2a. Downregulated miRNAs identified by deep sequencing of HNSCC clinical specimens   
MicroRNA Accession No. Location Log2 fold change 
FDR Normalized read count (Log2) 
(false discovery rate) Normal Cancer 
hsa-miR-375 MI0000783_1 2q35 -5.463 0.0484 14.39 8.93 
hsa-miR-133a-2 MI0000451_1 20q13.33 -4.535 0.3039 9.76 5.22 
hsa-miR-133a-1 MI0000450_1 18q11.2 -4.502 0.3054 9.75 5.25 
hsa-miR-150-3p MI0000479_1 19q13.33 -3.933 0.1521 5.70 1.76 
hsa-miR-1-2 MI0000437_1 18q11.2 -3.644 0.3857 14.68 11.04 
hsa-miR-1-1 MI0000651_1 20q13.33 -3.636 0.3864 14.72 11.08 
hsa-miR-135a-2-5p MI0000453_1 12q23.1 -3.307 0.1744 5.86 2.55 
hsa-miR-135a-1-5p MI0000452_2 3p21.1 -3.274 0.1746 5.81 2.53 
hsa-miR-885-5p MI0005560_2 3p25.3 -3.160 0.1094 4.14 0.98 
hsa-miR-4521 MI0016887_1 17p13 -3.107 0.1898 9.08 5.97 
hsa-miR-150-5p MI0000479_2 19q13.33 -2.910 0.2039 13.41 10.50 
hsa-miR-139-5p MI0000261_2 11q13.4 -2.863 0.0763 12.36 9.49 
hsa-miR-504 MI0003189_1 Xq26.3 -2.745 0.1818 7.43 4.69 
hsa-miR-497-5p MI0003138_2 17p13.1 -2.678 0.1496 7.89 5.21 
hsa-miR-99a-3p MI0000101_2 21q21.1 -2.446 0.0749 8.17 5.72 
hsa-miR-100-5p MI0000102_2 11q24.1 -2.438 0.1006 17.31 14.87 
hsa-miR-99a-5p MI0000101_1 21q21.1 -2.389 0.0107 18.21 15.83 
hsa-miR-125b-2-5p MI0000470_1 21q21.1 -2.373 0.0863 15.65 13.28 
hsa-miR-125b-1-5p MI0000446_2 11q24.1 -2.344 0.0882 15.64 13.29 
hsa-miR-338-3p MI0000814_1 17q25.3 -2.205 0.2557 6.28 4.07 
hsa-miR-582-5p MI0003589_2 5q12.1 -2.095 0.1636 8.05 5.95 
hsa-miR-451a MI0001729_1 17q11.2 -2.063 0.3321 14.56 12.50 
hsa-miR-887 MI0005562_1 5p15.1 -2.053 0.2633 5.06 3.00 
hsa-miR-1247-5p MI0006382_2 14q32.31 -2.034 0.2610 4.61 2.58 
hsa-miR-195-5p MI0000489_2 17p13.1 -2.028 0.1470 11.16 9.13 
hsa-miR-144-5p MI0000460_2 17q11.2 -1.963 0.2622 8.49 6.52 
hsa-let-7c MI0000064_1 21q21.1 -1.931 0.0432 15.29 13.36 
hsa-miR-29c-3p MI0000735_1 1q32.2 -1.929 0.3842 10.44 8.51 
hsa-miR-145-5p MI0000461_1 5q32 -1.927 0.1849 15.26 13.34 
hsa-miR-199b-5p MI0000282_2 9q34.11 -1.896 0.2647 16.03 14.13 
hsa-miR-29c-5p MI0000735_2 1q32.2 -1.872 0.2625 8.28 6.41 
hsa-miR-126-5p MI0000471_1 9q34.3 -1.836 0.2607 12.79 10.95 
hsa-miR-29a-3p MI0000087_1 7q32.3 -1.798 0.1147 14.70 12.91 
hsa-miR-664-3p MI0006442_1 1q41 -1.781 0.1149 9.84 8.06 
hsa-miR-125b-1-3p MI0000446_1 11q24.1 -1.723 0.2313 8.69 6.96 
hsa-miR-140-3p MI0000456_2 16q22.1 -1.721 0.1487 14.08 12.36 
hsa-miR-338-5p MI0000814_2 17q25.3 -1.703 0.2685 7.45 5.75 
hsa-miR-486-5p MI0002470_2 8p11.21 -1.702 0.2652 11.98 10.27 
hsa-miR-10b-5p MI0000267_1 2q31.1 -1.682 0.0482 17.08 15.40 
hsa-miR-29a-5p MI0000087_2 7q32.3 -1.648 0.4284 4.44 2.79 
hsa-miR-1468 MI0003782_1 Xq11 -1.611 0.2468 4.65 3.03 
hsa-miR-10b-3p MI0000267_2 2q31.1 -1.585 0.1037 6.49 4.91 
hsa-miR-140-5p MI0000456_1 16q22.1 -1.582 0.2556 11.22 9.64 
hsa-miR-195-3p MI0000489_1 17p13.1 -1.565 0.3212 8.58 7.02 
hsa-miR-203 MI0000283_1 14q32.33 -1.564 0.3170 17.58 16.02 
hsa-miR-585 MI0003592_1 5q35.1 -1.564 0.1830 6.76 5.20 
hsa-miR-126-3p MI0000471_2 9q34.3 -1.560 0.1626 17.53 15.97 
hsa-miR-145-3p MI0000461_2 5q32 -1.552 0.2569 9.56 8.01 
hsa-miR-26b-5p MI0000084_1 2q35 -1.547 0.0804 15.66 14.12 
hsa-miR-29b-2-5p MI0000107_2 1q32.2 -1.531 0.1254 6.52 4.99 
hsa-miR-154-5p MI0000480_1 14q32.31 -1.524 0.2568 5.64 4.11 
hsa-miR-146a-5p MI0000477_1 5q33.3 -1.502 0.2794 13.38 11.88 
hsa-miR-26b-3p MI0000084_2 2q35 -1.498 0.0527 6.80 5.30 
hsa-miR-3065-5p MI0014228_1 17q25 -1.491 0.2236 8.22 6.73 
hsa-miR-378a-5p MI0000786_1 5q32 -1.442 0.2016 8.68 7.24 
hsa-miR-664-5p MI0006442_2 1q41 -1.438 0.2612 6.71 5.27 
hsa-miR-342-5p MI0000805_1 14q32.2 -1.434 0.1295 7.42 5.98 
hsa-miR-644b-3p MI0019134_2 20q11.22 -1.425 0.2828 5.97 4.54 
hsa-miR-125a-5p MI0000469_1 19q13.41 -1.410 0.3695 14.68 13.27 
hsa-miR-1255a MI0006389_1 4q24 -1.397 0.2672 4.30 2.90 
hsa-miR-125b-2-3p MI0000470_2 21q21.1 -1.375 0.1042 7.40 6.02 
hsa-miR-143-3p MI0000459_2 5q32 -1.368 0.3447 19.41 18.04 
hsa-miR-26a-2-5p MI0000750_2 12q14.1 -1.347 0.2606 18.44 17.09 
hsa-miR-26a-1-5p MI0000083_1 3p22.2 -1.345 0.2612 18.45 17.11 
hsa-miR-328 MI0000804_1 16q22.1 -1.299 0.2026 9.60 8.30 
hsa-miR-197-3p MI0000239_2 1p13.3 -1.269 0.2220 10.84 9.57 
hsa-miR-30a-3p MI0000088_1 6q13 -1.262 0.3886 10.12 8.86 
hsa-miR-378g MI0016761_1 1p21 -1.258 0.2025 7.32 6.06 
hsa-miR-485-5p MI0002469_1 14q32.31 -1.239 0.2813 6.30 5.07 
hsa-miR-342-3p MI0000805_2 14q32.2 -1.234 0.0529 12.11 10.88 
hsa-miR-199a-2-3p MI0000281_1 1q24.3 -1.218 0.2659 16.08 14.86 
hsa-miR-199a-1-3p MI0000242_1 19p13.2 -1.217 0.2625 16.08 14.86 
hsa-miR-199b-3p MI0000282_1 9q34.11 -1.217 0.2644 16.08 14.86 
hsa-miR-378a-3p MI0000786_2 5q32 -1.212 0.1371 15.89 14.67 
hsa-miR-186-5p MI0000483_2 1p31.1 -1.170 0.1098 12.95 11.78 
hsa-miR-146a-3p MI0000477_2 5q33.3 -1.160 0.4081 4.07 2.91 
hsa-miR-574-3p MI0003581_2 4p14 -1.153 0.2135 11.58 10.43 
hsa-miR-378i MI0016902_1 22q13.2 -1.153 0.2594 4.38 3.23 
hsa-miR-30e-3p MI0000749_2 1p34.2 -1.138 0.2616 11.47 10.33 
hsa-miR-200b-5p MI0000342_1 1p36.33 -1.100 0.2299 9.24 8.14 
hsa-miR-3065-3p MI0014228_2 17q25 -1.080 0.2784 5.47 4.39 
hsa-miR-3912 MI0016416_1 5q35.1 -1.066 0.4073 4.99 3.93 
hsa-let-7e-3p MI0000066_2 19q13.41 -1.064 0.2466 6.42 5.36 
hsa-miR-326 MI0000808_1 11q13.4 -1.061 0.2804 6.10 5.04 
hsa-let-7b-3p MI0000063_2 22q13.31 -1.055 0.3603 8.28 7.23 
hsa-miR-874 MI0005532_1 5q31.2 -1.046 0.3647 8.80 7.76 
hsa-miR-30b-5p MI0000441_2 8q24.22 -1.004 0.0890 13.59 12.58 
hsa-miR-2110 MI0010629_1 10q25.3 -0.977 0.2023 7.55 6.58 
hsa-miR-628-5p MI0003642_2 15q21.3 -0.974 0.3709 6.09 5.12 
hsa-miR-30c-1-5p MI0000736_1 1p34.2 -0.951 0.2704 14.51 13.56 
hsa-miR-30c-2-5p MI0000254_2 6q13 -0.947 0.2705 14.48 13.53 
hsa-miR-10a-5p MI0000266_2 17q21.32 -0.940 0.3895 15.98 15.04 
hsa-miR-487b MI0003530_1 14q32.31 -0.908 0.2734 6.26 5.36 
hsa-miR-30c-1-3p MI0000736_2 1p34.2 -0.904 0.3419 6.61 5.71 
hsa-miR-625-5p MI0003639_1 14q23.3 -0.901 0.4267 4.82 3.92 
hsa-miR-942 MI0005767_1 1p13.1 -0.879 0.0563 5.30 4.42 
hsa-let-7g-5p MI0000433_2 3p21.1 -0.864 0.1955 18.05 17.18 
hsa-miR-502-3p MI0003186_2 Xp11.23 -0.840 0.0780 9.74 8.90 
hsa-miR-379-5p MI0000787_1 14q32.31 -0.822 0.3836 10.64 9.82 
hsa-miR-576-5p MI0003583_1 4q25 -0.800 0.2818 7.31 6.51 
hsa-miR-625-3p MI0003639_2 14q23.3 -0.791 0.2592 7.52 6.72 
hsa-miR-660-5p MI0003684_1 Xp11.23 -0.787 0.3009 11.20 10.42 
hsa-miR-374a-5p MI0000782_2 Xq13.2 -0.783 0.2790 10.76 9.98 
hsa-miR-378c MI0015825_1 10q26.3 -0.769 0.4066 11.07 10.30 
hsa-miR-148a-3p MI0000253_1 7p15.2 -0.712 0.3867 18.30 17.59 
hsa-miR-191-5p MI0000465_2 3p21.31 -0.704 0.3450 14.72 14.02 
hsa-miR-30b-3p MI0000441_1 8q24.22 -0.674 0.2607 5.90 5.23 
hsa-miR-3158-2-3p MI0014187_1 10q24.3 -0.607 0.2657 6.08 5.47 
hsa-miR-200b-3p MI0000342_2 1p36.33 -0.593 0.3704 16.88 16.29 
hsa-miR-148a-5p MI0000253_2 7p15.2 -0.592 0.4111 10.55 9.96 
hsa-miR-3158-1-3p MI0014186_2 10q24.3 -0.589 0.2550 6.10 5.51 
hsa-miR-320a MI0000542_1 8p21.3 -0.571 0.2265 14.29 13.72 
hsa-miR-374b-5p MI0005566_2 Xq13.2 -0.561 0.1507 12.35 11.79 
hsa-miR-16-2-5p MI0000115_1 3q25.33 -0.515 0.3798 13.21 12.70 
hsa-miR-16-1-5p MI0000070_2 13q14.2 -0.505 0.3848 13.22 12.71 
hsa-miR-141-3p MI0000457_2 12p13.31 -0.402 0.4244 10.99 10.59 
       
Table 2b. Upregulated miRNAs identified by deep sequencing of HNSCC clinical specimens   
MicroRNA Accession No. Location Log2 fold change 
FDR Normalized read count (Log2) 
(false discovery rate) Normal Cancer 
hsa-miR-615-3p MI0003628_2 12q13.13 5.145 0.1353 2.82 7.97 
hsa-miR-196b-5p MI0001150_2 7p15.2 3.075 0.0138 5.91 8.98 
hsa-miR-187-3p MI0000274_1 18q12.2 2.383 0.2044 5.33 7.71 
hsa-miR-503 MI0003188_1 Xq26.3 2.165 0.1995 5.87 8.03 
hsa-miR-542-3p MI0003686_1 Xq26.3 2.115 0.1023 6.80 8.91 
hsa-miR-450b-5p MI0005531_2 Xq26.3 2.057 0.1723 7.03 9.09 
hsa-miR-34c-5p MI0000743_1 11q23.1 1.820 0.4197 9.72 11.54 
hsa-miR-450a-2-5p MI0003187_2 Xq26.3 1.787 0.1213 7.12 8.91 
hsa-miR-424-3p MI0001446_1 Xq26.3 1.783 0.3713 6.13 7.91 
hsa-miR-450a-1-5p MI0001652_1 Xq26.3 1.782 0.1227 7.12 8.90 
hsa-miR-7a-1-5p MI0000263_2 9q22.32 1.771 0.0596 13.48 15.25 
hsa-miR-7a-3-5p MI0000265_1 22q13.31 1.763 0.0566 13.43 15.19 
hsa-miR-7a-2-5p MI0000264_1 11q24.1 1.759 0.0542 13.44 15.20 
hsa-miR-9-3-5p MI0000468_1 15q26.1 1.692 0.2772 9.88 11.57 
hsa-miR-9-1-5p MI0000466_2 1q22 1.687 0.2784 9.85 11.54 
hsa-miR-9-2-5p MI0000467_2 5q14.3 1.687 0.2769 9.85 11.54 
hsa-miR-21-5p MI0000077_1 17q23.1 1.597 0.1526 19.70 21.30 
hsa-miR-21-3p MI0000077_2 17q23.1 1.548 0.1204 11.11 12.66 
hsa-miR-4664-3p MI0017294_1 8q24.3 1.455 0.2223 4.57 6.03 
hsa-miR-424-5p MI0001446_2 Xq26.3 1.405 0.2095 7.00 8.40 
hsa-miR-25-5p MI0000082_2 7q22.1 1.398 0.1087 6.10 7.50 
hsa-miR-147b MI0005544_1 15q21.1 1.364 0.2026 5.43 6.79 
hsa-miR-708-3p MI0005543_1 11q14.1 1.297 0.4250 8.49 9.79 
hsa-miR-1301 MI0003815_1 2p23 1.158 0.2603 6.99 8.15 
hsa-miR-548k MI0006354_1 11q13.3 1.144 0.3456 6.79 7.94 
hsa-miR-671-5p MI0003760_1 7q36.1 1.137 0.1549 7.76 8.89 
hsa-miR-2355-3p MI0015873_1 2q33 1.135 0.2624 3.84 4.97 
hsa-miR-550a-2-5p MI0003601_1 7p14.3 1.130 0.1268 3.64 4.77 
hsa-miR-550a-1-5p MI0003600_1 7p14.3 1.130 0.1295 3.64 4.77 
hsa-miR-944 MI0005769_1 3q28 1.062 0.3709 9.37 10.43 
hsa-miR-106b-3p MI0000734_1 7q22.1 1.036 0.2602 10.61 11.64 
hsa-miR-5001-3p MI0017867_1 2q37.1 1.033 0.3864 3.84 4.88 
hsa-miR-877-5p MI0005561_1 6p21.33 1.030 0.1822 5.90 6.93 
hsa-miR-18a-5p MI0000072_1 13q31.3 0.981 0.1865 7.25 8.23 
hsa-miR-335-3p MI0000816_2 7q32.2 0.853 0.4126 9.44 10.29 
hsa-miR-92b-3p MI0003560_2 1q22 0.791 0.2816 9.68 10.47 
hsa-miR-149-5p MI0000478_1 2q37.3 0.763 0.1446 10.88 11.64 
hsa-miR-455-5p MI0003513_1 9q32 0.753 0.2654 11.66 12.41 
hsa-miR-93-3p MI0000095_1 7q22.1 0.654 0.1612 6.52 7.17 
hsa-miR-25-3p MI0000082_1 7q22.1 0.643 0.3837 13.82 14.47 
hsa-miR-454-3p MI0003820_1 17q22 0.627 0.2798 8.73 9.36 
hsa-miR-330-5p MI0000803_2 19q13.32 0.593 0.3877 6.56 7.15 
hsa-miR-93-5p MI0000095_2 7q22.1 0.545 0.4288 13.03 13.57 
hsa-miR-152 MI0000462_1 17q21.32 0.387 0.3723 13.62 14.01 
hsa-miR-3934 MI0016590_1 6p21.3 0.237 0.3291 5.63 5.87 
 
Table 3. Significantly enriched annotations regulated by miR-150-5p 
Number of genes P-value Annotations 
33 7.22E-06 (KEGG) 05200: Pathways in cancer 
22 3.43E-06 (KEGG) 03013: RNA transport 
21 1.01E-05 (KEGG) 04141: Protein processing in endoplasmic reticulum 
20 1.04E-02 (KEGG) 04010: MAPK signaling pathway 
20 7.57E-06 (KEGG) 04120: Ubiquitin mediated proteolysis 
20 2.30E-06 (KEGG) 04110: Cell cycle 
18 3.57E-04 (KEGG) 00230: Purine metabolism 
17 5.42E-04 (KEGG) 04310: Wnt signaling pathway 
16 1.40E-02 (KEGG) 04510: Focal adhesion 
16 1.03E-05 (KEGG) 00240: Pyrimidine metabolism 
15 1.17E-03 (KEGG) 05162: Measles 
14 2.82E-02 (KEGG) 05016: Huntington's disease 
14 4.34E-03 (KEGG) 04910: Insulin signaling pathway 
14 2.21E-03 (KEGG) 04722: Neurotrophin signaling pathway 
14 4.73E-05 (KEGG) 05222: Small cell lung cancer 
14 1.03E-05 (KEGG) 03008: Ribosome biogenesis in eukaryotes 
14 1.03E-05 (KEGG) 05220: Chronic myeloid leukemia 
13 4.22E-03 (KEGG) 03040: Spliceosome 
12 1.79E-02 (KEGG) 05160: Hepatitis C 
12 1.10E-03 (KEGG) 05215: Prostate cancer 
11 2.57E-02 (KEGG) 05145: Toxoplasmosis 
10 2.67E-02 (KEGG) 04660: T cell receptor signaling pathway 
10 8.29E-03 (KEGG) 04210: Apoptosis 
10 5.60E-03 (KEGG) 00564: Glycerophospholipid metabolism 
10 5.60E-03 (KEGG) 03015: mRNA surveillance pathway 
10 1.72E-04 (KEGG) 00510: N-Glycan biosynthesis 
9 2.15E-02 (KEGG) 04012: ErbB signaling pathway 
9 7.54E-03 (KEGG) 05212: Pancreatic cancer 
9 7.54E-03 (KEGG) 05211: Renal cell carcinoma 
9 5.90E-03 (KEGG) 04115: p53 signaling pathway 
9 5.90E-03 (KEGG) 04920: Adipocytokine signaling pathway 
9 5.40E-04 (KEGG) 04330: Notch signaling pathway 
8 2.68E-02 (KEGG) 04662: B cell receptor signaling pathway 
8 1.19E-02 (KEGG) 05214: Glioma 
8 1.01E-02 (KEGG) 04623: Cytosolic DNA-sensing pathway 
8 1.03E-04 (KEGG) 03020: RNA polymerase 
7 1.47E-02 (KEGG) 04150: mTOR signaling pathway 
7 5.77E-03 (KEGG) 03420: Nucleotide excision repair 
7 5.68E-03 (KEGG) 00970: Aminoacyl-tRNA biosynthesis 
6 4.91E-02 (KEGG) 05223: Non-small cell lung cancer 
6 2.93E-02 (KEGG) 00561: Glycerolipid metabolism 
6 1.95E-02 (KEGG) 05219: Bladder cancer 
6 1.63E-02 (KEGG) 03050: Proteasome 
6 9.83E-03 (KEGG) 04130: SNARE interactions in vesicular transport 
6 9.83E-03 (KEGG) 03030: DNA replication 
6 8.16E-03 (KEGG) 03410: Base excision repair 
5 1.27E-02 (KEGG) 00534: Glycosaminoglycan biosynthesis - heparan sulfate 
5 1.12E-02 (KEGG) 00563: Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 
4 3.60E-02 (KEGG) 04320: Dorso-ventral axis formation 
4 3.12E-02 (KEGG) 00532: Glycosaminoglycan biosynthesis - chondroitin sulfate 
4 1.83E-02 (KEGG) 00670: One carbon pool by folate 
3 2.79E-02 (KEGG) 00740: Riboflavin metabolism 
 
Table 4. Significantly enriched annotations regulated by miR-150-3p 
Number of genes P-value Annotations 
16 0.0024 (KEGG) 05200: Pathways in cancer 
10 0.0386 (KEGG) 04510: Focal adhesion 
8 0.0021 (KEGG) 04520: Adherens junction 
8 0.0036 (KEGG) 05222: Small cell lung cancer 
4 0.0349 (KEGG) 00020: Citrate cycle (TCA cycle) 
 
Table 5. Focal adhesion pathway regulated by miR-150-5p     
Gene Symbol Gene Name conserved 
poorly 
conserved 
GEO9638 
log2 ratio 
GSE82108 
log2 ratio 
TNC  tenascin C  0 3 1.416 -0.899 
ITGA6  integrin, alpha 6  0 2 1.105 -0.052 
VAV2  vav 2 guanine nucleotide exchange factor  0 2 0.976 -0.169 
SHC1  SHC (Src homology 2 domain containing) transforming protein 1  0 1 0.933 -0.804 
VEGFA  vascular endothelial growth factor A  0 1 0.653 -0.265 
GSK3B  glycogen synthase kinase 3 beta  1 0 0.606 -0.089 
ITGA3  integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)  0 9 0.583 -0.058 
AKT2  v-akt murine thymoma viral oncogene homolog 2  0 2 0.533 -0.308 
CAV2  caveolin 2  0 1 0.443 -0.914 
ROCK1  Rho-associated, coiled-coil containing protein kinase 1  1 0 0.441 -0.226 
GRB2  growth factor receptor-bound protein 2  0 2 0.382 -0.148 
XIAP  X-linked inhibitor of apoptosis  0 3 0.341 -0.456 
TNR  tenascin R (restrictin, janusin)  0 2 0.263 -0.285 
TLN1  talin 1  0 3 0.165 -0.190 
PIK3CB  phosphoinositide-3-kinase, catalytic, beta polypeptide  1 0 0.092 -0.068 
CRK  v-crk sarcoma virus CT10 oncogene homolog (avian)  0 1 0.001 -0.069 
 
Table 6. Focal adhesion pathway regulated by miR-150-3p    
Gene Symbol Gene Name 
poorly 
conserved 
GSE9638 
log2 ratio 
GSE82108 
log2 ratio 
LAMC2  laminin, gamma 2 1 2.334 -0.8519 
EGFR  epidermal growth factor receptor  1 1.835 -0.6698 
TNC  tenascin C  1 1.416 -0.7192 
ITGA6  integrin, alpha 6 1 1.105 -0.1906 
IGF1R  insulin-like growth factor 1 receptor  1 0.611 -0.0533 
PTK2  PTK2 protein tyrosine kinase 2 1 0.605 -0.4804 
ITGA3  integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 1 0.583 -0.2200 
CAV2  caveolin 2 1 0.443 -0.6686 
XIAP  X-linked inhibitor of apoptosis  1 0.341 -0.0765 
THBS1  thrombospondin 1 2 0.189 -0.1310 
 
Supplementary Table1. Details of sequence reads             
Normal epithelia samples #1   #2   #3   #4   #5   #6   
  Count (%) Count (%) Count (%) Count (%) Count (%) Count (%) 
Total reads 23679339 100 21946900 100 18443975 100 24404638 100 16558041 100 12180452 100 
  5'adapter contaminants 7895 0.03 8458 0.04 10466 0.06 6853 0.03 1898 0.01 2339 0.02 
  3'adapter null 6391072 26.99 7153930 32.6 4964350 26.92 6692336 27.42 1151592 6.95 2543856 20.88 
  Insert null 79308 0.33 93050 0.42 120598 0.65 88669 0.36 86351 0.52 188043 1.54 
  Smaller than 15 nt 381930 1.61 476567 2.17 229982 1.25 155685 0.64 437128 2.64 149148 1.22 
  Longer than 28 nt 6783219 28.65 5494176 25.03 5447702 29.54 6020872 24.67 3193007 19.28 2604380 21.38 
  Poly A 91 0 141 0 116 0 56 0 184 0 22 0 
  Clean Reads 10035824 42.38 8720578 39.73 7670761 41.59 11440167 46.88 11687881 70.59 6692664 54.95 
HNSCC samples #1   #2   #3   #4   #5   #6   
  Count (%) Count (%) Count (%) Count (%) Count (%) Count (%) 
Total reads 21362445 100 19174524 100 21930947 100 22141929 100 21717298 100 24845427 100 
  5'adapter contaminants 6126 0.03 5234 0.03 4818 0.02 4299 0.02 5264 0.02 3473 0.01 
  3'adapter null 6287386 29.43 6793708 35.43 5858570 26.71 3946545 17.82 4296546 19.78 3015325 12.14 
  Insert null 89452 0.42 34526 0.18 38111 0.17 55479 0.25 76408 0.35 66033 0.27 
  Smaller than 15 nt 323869 1.52 269427 1.41 514685 2.35 209630 0.95 328658 1.51 241859 0.97 
  Longer than 28 nt 5477464 25.64 5773018 30.11 6774839 30.89 6741506 30.45 3255544 14.99 5349161 21.53 
  Poly A 112 0 46 0 87 0 95 0 37 0 62 0 
  Clean Reads 9178036 42.96 6298565 32.85 8739837 39.85 11184375 50.51 13754841 63.34 16169514 65.08 
 
Supplementary Table 2. Details of Alignment Statistics         
Normal epithelia samples #1   #2   #3   #4   #5   #6   
  Count (%) Count (%) Count (%) Count (%) Count (%) Count (%) 
Clean Reads 10035824 100 8720578 100 7670761 100 11440167 100 11687881 100 6692664 100 
Aligned reads 7826695 78 6763551 77.6 6060029 79 9515626 83.2 9598214 82.1 5664692 84.6 
   - Uniquely matched reads 6051673 60.3 5520277 63.3 4633968 60.4 7667510 67 7566886 64.7 4435139 66.3 
   - Multiply matched reads 1775022 17.7 1243274 14.3 1426061 18.6 1848116 16.2 2031328 17.4 1229553 18.4 
Unaligned reads 2056201 20.5 1782517 20.4 1487183 19.4 1838872 16.1 1940248 16.6 983994 14.7 
   - No matches found 1806140 18 1595243 18.3 1328557 17.3 1670868 14.6 1715989 14.7 887846 13.3 
   - Too many matches 250061 2.5 187274 2.1 158626 2.1 168004 1.5 224259 1.9 96148 1.4 
Number of locations aligned Uniquely and Multiply matched reads 9004184  7619508  7081118  10886607  11021661  6736173  
HNSCC samples #1   #2   #3   #4   #5   #6   
  Count (%) Count (%) Count (%) Count (%) Count (%) Count (%) 
Clean Reads 9178036 100 6298565 100 8739837 100 11184375 100 13754841 100 16169514 100 
Aligned reads 7114159 77.5 4965770 78.8 6053433 69.3 9145089 81.8 11597592 84.3 13573321 83.9 
   - Uniquely matched reads 5877644 64 4089163 64.9 4601566 52.7 8043485 71.9 9465308 68.8 11000284 68 
   - Multiply matched reads 1236515 13.5 876607 13.9 1451867 16.6 1101604 9.8 2132284 15.5 2573037 15.9 
Unaligned reads 1933101 21.1 1239192 19.7 2421581 27.7 1965018 17.6 2086889 15.2 2494236 15.4 
   - No matches found 1714741 18.7 1055087 16.8 1981443 22.7 1790540 16 1912633 13.9 2280134 14.1 
   - Too many matches 218360 2.4 184105 2.9 440138 5 174478 1.6 174256 1.3 214102 1.3 
Number of locations aligned Uniquely and Multiply matched reads 8085627   5690747   7502945   10025234   13663064   15951587   
 
Supplementary Table 3. Annotation of reads aligned to small RNAs 
Normal epithelia samples #1   #2   #3   #4   #5   #6   
  Count (%) Count (%) Count (%) Count (%) Count (%) Count (%) 
Total locations 9004184 100 7619508 100 7081118 100 10886607 100 11021661 100 6736173 100 
miRNA 7985677 88.69 6665278 87.48 5980706 84.46 9905833 90.99 9722647 88.21 6057813 89.93 
scRNA 7304 0.08 5941 0.08 5468 0.08 5291 0.05 7826 0.07 5692 0.08 
scRNA_pseudo 3710 0.04 2007 0.03 2972 0.04 1348 0.01 1681 0.02 1104 0.02 
snRNA 19246 0.21 40205 0.53 8143 0.11 5765 0.05 9836 0.09 3183 0.05 
snRNA_pseudo 170 0.00 723 0.01 59 0.00 31 0.00 30 0.00 15 0.00 
snoRNA 766558 8.51 691987 9.08 910311 12.86 780185 7.17 1069951 9.71 586812 8.71 
snoRNA_pseudo 37 0.00 34 0.00 41 0.00 60 0.00 167 0.00 49 0.00 
tRNA 125358 1.39 107289 1.41 93618 1.32 102256 0.94 81339 0.74 38784 0.58 
tRNA_pseudo 1526 0.02 1148 0.02 919 0.01 1236 0.01 1067 0.01 761 0.01 
Unknown 94598 1.05 104896 1.38 78881 1.11 84602 0.78 127117 1.15 41960 0.62 
HNSCC samples #1   #2   #3   #4   #5   #6   
  Count (%) Count (%) Count (%) Count (%) Count (%) Count (%) 
Total locations 8085627 100 5690747 100 7502945 100 10025234 100 13663064 100 15951587 100 
miRNA 7215729 89.24 5101981 89.65 6428347 85.68 9283993 92.61 12852920 94.07 14811960 92.86 
scRNA 19098 0.24 9312 0.16 15689 0.21 7521 0.08 8438 0.06 18489 0.12 
scRNA_pseudo 6804 0.08 1585 0.03 4097 0.05 1331 0.01 1600 0.01 2611 0.02 
snRNA 11610 0.14 22812 0.40 46239 0.62 18325 0.18 16682 0.12 41466 0.26 
snRNA_pseudo 141 0.00 71 0.00 247 0.00 24 0.00 47 0.00 71 0.00 
snoRNA 625071 7.73 394915 6.94 657859 8.77 514946 5.14 631060 4.62 899820 5.64 
snoRNA_pseudo 72 0.00 68 0.00 134 0.00 94 0.00 215 0.00 240 0.00 
tRNA 143407 1.77 104766 1.84 266087 3.55 136841 1.36 89807 0.66 105502 0.66 
tRNA_pseudo 1338 0.02 1766 0.03 2813 0.04 1657 0.02 1272 0.01 1481 0.01 
Unknown 62357 0.77 53471 0.94 81433 1.09 60502 0.60 61023 0.45 69947 0.44 
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